Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Transplantation and Cellular TherapyOpen Access

Belumosudil for Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

KRKristin RathjeNGNico GagelmannSHSilke Heidenreich

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis indicate improved efficacy in refractory cGvHD, suggesting further treatment exploration.

Key Points

  • This review aims to assess the efficacy and safety of belumosudil in chronic graft-versus-host disease.
  • Conducted a systematic review and meta-analysis of studies assessing belumosudil use in cGvHD.
  • Included studies focused on patients with refractory cGvHD.
  • Evaluated treatment outcomes and adverse effects.
  • Belumosudil demonstrated promising efficacy in treating refractory cGvHD.
  • The safety profile of belumosudil was favorable during treatment.
  • Findings support the need for future investigations into earlier interventions in cGvHD.

Cite This Study

Rathje et al. (2025) studied this question.

synapsesocial.com/papers/69254377c0ce034ddc358cfahttps://doi.org/10.1016/j.jtct.2025.11.019
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft‐Versus‐Host Disease: A Systematic Review and Meta‐Analysis2026
  2. 2Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety2025
  3. 3Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease2025
  4. 4Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US2025
  5. 5Belumosudil for chronic graft-versus-host disease2022 · 8 citations